Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using finasteride for 7 months and is inquiring about Thrive's hair serum, which contains redensyl, procapil, and anagain, seeking feedback from others who have used it.

Dutasteride taken three times a week is more effective for hair regrowth than daily finasteride, with fewer side effects. Some users combine dutasteride and finasteride for better results, while others prefer dutasteride alone due to its longer half-life and potential fertility concerns.

Dutasteride is effective for hair loss but may cause side effects like decreased sperm count, which might not fully recover after stopping. Users discuss balancing dosages to minimize side effects while maintaining benefits.

Hair loss treatment with Finasteride, Ketoconazole, Microneedling, Biotin, and Vitamin E shows progress. Users agree hairline improved and suggest continuing treatment.

A 29-year-old man has seen hair growth progress over 5 months using daily 1mg finasteride and topical minoxidil, along with ketoconazole shampoo and dermarolling three times a week. After trying various unsuccessful treatments, he's satisfied with these results.

The user has been using minoxidil 5% at night, finasteride 1mg daily, dutasteride 0.5mg weekly, microneedling weekly, Nizoral 1% shampoo, and apple cider vinegar hair wash. They recently started taking oral minoxidil 2.5-5mg and report no side effects.

A user is considering taking oral minoxidil 3mg every other day or thrice a week to minimize side effects and save money. They seek opinions on this dosing strategy.

A user started taking 1mg finasteride for hair loss and plans to follow a thrice-weekly dosing schedule recommended by two doctors. They previously used saw palmetto without issues and are hopeful finasteride won't cause sexual side effects.

The user shared progress after using 5% minoxidil twice daily, 0.2% topical finasteride once daily, Nizoral shampoo thrice weekly, and microneedling weekly for hair loss. They observed thicker hair after 12-14 months and are curious about further improvement.

The conversation is about hair loss treatment progress using 2.5mg oral Minoxidil daily, derma rolling weekly, and Ketoconazole shampoo thrice weekly, with plans to add oral Dutasteride. Users discuss the potential benefits and timing of using Dutasteride for hair recovery.

The user regained hair and reduced forehead size using a routine of 1mg finasteride, 5mg minoxidil, topical minoxidil twice daily, tretinoin before minoxidil, derma stamping weekly, red light therapy daily, and ketoconazole shampoo thrice weekly. They experienced initial side effects with finasteride but adjusted the dosage over time.

A user shared their 5-month hair loss treatment progress, using 1mg finasteride, daily GHK-CU injections, keratin/biotin/MSM supplements, Pura D’Or shampoo and conditioner, Ayurvedic oil, ketoconazole thrice weekly, and weekly microneedling with topical GHK-CU. The post includes progress pictures.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

A 19-year-old is using keto shampoo, topical Minoxidil 5% for 3 months, and topical finasteride 0.1% for 1.5 months to address hair loss. They are noticing baby hairs and shedding, questioning if the hairs will thicken and if more time is needed for finasteride to work.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

The conversation humorously discusses various methods of applying minoxidil for hair loss, with some users suggesting oral minoxidil as a more convenient option despite potential side effects. The original poster jokes about using a red light helmet with mesotherapy needles for continuous minoxidil application.